Axsome Stock Analysis

AXSM Stock  USD 61.96  0.05  0.08%   
The recent Axsome Therapeutics price decline could raise concerns from insiders as the firm is trading at a share price of 61.96 on very low momentum in volume. The company executives were unable to exploit market volatilities in February. However, diversifying your overall positions with Axsome Therapeutics can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.05. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Axsome Therapeutics partners.
Check out Trending Equities. To learn how to invest in Axsome Stock please use our How to Invest in Axsome Therapeutics guide.
The main objective of Axsome Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Axsome Therapeutics is worth, separate from its market price. There are two main types of Axsome Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Axsome Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Axsome Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Axsome Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Axsome Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, Christmas Day ( substitute day ), New Year 's Monday, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Axsome Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Axsome Therapeutics' ongoing operational relationships across important fundamental and technical indicators.

Axsome Stock Analysis Notes

About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.5. Axsome Therapeutics had not issued any dividends in recent years. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. For more info on Axsome Therapeutics please contact Herriot Tabuteau at 212 332 3241 or go to

Axsome Therapeutics Quarterly Cost of Revenue

2.29 Million

Axsome Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Axsome Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Axsome Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Axsome Therapeutics generated a negative expected return over the last 90 days
Axsome Therapeutics has high historical volatility and very poor performance
Axsome Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 50.04 M. Net Loss for the year was (187.13 M) with profit before overhead, payroll, taxes, and interest of 45.94 M.
Axsome Therapeutics currently holds about 73.39 M in cash with (116.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Axsome Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 71.0% of the company shares are held by institutions such as insurance companies
Latest headline from Got 2000 3 Growth Stocks to Buy That Could Double Your Money - Nasdaq

Axsome Therapeutics Upcoming and Recent Events

Earnings reports are used by Axsome Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of May 2023
Upcoming Quarterly Report
8th of August 2023
Next Financial Report
31st of March 2023
Next Fiscal Quarter End
26th of February 2024
Next Fiscal Year End
31st of December 2022
Last Quarter Report
31st of December 2022
Last Financial Announcement

Axsome Largest EPS Surprises

Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates
View All Earnings Estimates

Axsome Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Axsome Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Axsome Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Axsome Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
13th of March 2023
Financial Statements and Exhibits. Regulation FD Disclosure
10th of March 2023
Financial Statements and Exhibits. Regulation FD Disclosure
27th of February 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
22nd of February 2023
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
14th of February 2023
Unclassified Corporate Event
13th of February 2023
Other Events
9th of February 2023
Unclassified Corporate Event
1st of February 2023
Unclassified Corporate Event

Axsome Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Axsome Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Therapeutics backward and forwards among themselves. Axsome Therapeutics' institutional investor refers to the entity that pools money to purchase Axsome Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Vanguard Group Inc2022-12-31Common Shares3.4 M263.6 M
Rtw Investments Lp2022-12-31Common SharesM229.9 M
Blackrock Inc2022-12-31Common Shares2.5 M193.1 M
Fairmount Funds Management Llc2022-12-31Common SharesM155.2 M
Bvf Inc2022-12-31Common Shares1.8 M135.4 M
Pfm Health Sciences Lp2022-12-31Common Shares1.1 M84.3 M
Adage Capital Partners Gp Llc2022-12-31Common Shares1.1 M82.1 M
Alethea Capital Management Llc2022-12-31Common Shares785.7 K60.6 M
State Street Corp2022-12-31Common Shares756.9 K58.4 M
Fmr Llc2022-12-31Common Shares734.4 K56.6 M
Vr Adviser Llc2022-12-31Common Shares670.7 K51.7 M
Note, although Axsome Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Axsome Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.7 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Axsome Therapeutics's market, we take the total number of its shares issued and multiply it by Axsome Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Axsome Profitablity

Axsome Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Axsome Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Axsome Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Axsome Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Axsome Therapeutics' profitability requires more research than a typical breakdown of Axsome Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Investment(118.31) (127.65) 
Return on Average Assets(0.80) (0.86) 
Return on Average Equity(2.52) (2.59) 
Return on Invested Capital(2.94) (3.02) 
Return on Sales(3.23) (3.49) 

Management Efficiency

The entity has return on total asset (ROA) of (0.5215) % which means that it has lost $0.5215 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.9897) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics management efficiency ratios could be used to measure how well axsome therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 26th of March 2023, Return on Investment is likely to drop to -127.65. In addition to that, Return on Average Assets is likely to drop to -0.86. Axsome Therapeutics Average Assets are very stable at the moment as compared to the past year. Axsome Therapeutics reported last year Average Assets of 234.89 Million. As of 26th of March 2023, Tangible Asset Value is likely to grow to about 282.2 M, while Goodwill and Intangible Assets are likely to drop about 62.6 M.
Last ReportedProjected for 2023
Book Value per Share 2.69  2.38 
Enterprise Value over EBIT(18.00) (19.42) 
Enterprise Value over EBITDA(18.46) (19.92) 
Price to Book Value 30.57  36.02 
Tangible Assets Book Value per Share 6.43  6.94 
Enterprise Value3.2 B3.5 B
Tangible Asset Value261.5 M282.2 M
The analysis of Axsome Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Axsome Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Axsome Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Non Current Liabilities Total
125.4 M
Short Long Term Debt Total
94.7 M
Interest Expense
7.3 M
Total Operating Expenses
229.8 M

Technical Drivers

As of the 26th of March, Axsome Therapeutics shows the mean deviation of 2.3, and Risk Adjusted Performance of (0.08). Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Axsome Therapeutics, which can be compared to its rivals. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 61.96 per share. Given that Axsome Therapeutics has jensen alpha of (0.25), we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Axsome Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Axsome Therapeutics changes than the simple moving average.

Axsome Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Axsome Therapeutics Technical and Predictive Indicators

Axsome Therapeutics Forecast Models

Axsome Therapeutics time-series forecasting models is one of many Axsome Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Axsome Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Axsome Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Axsome Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Axsome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Axsome Therapeutics. By using and applying Axsome Stock analysis, traders can create a robust methodology for identifying Axsome entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(3.13) (3.38) 
Gross Margin 0.81  0.81 
Profit Margin(3.37) (3.63) 

Current Axsome Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Axsome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Axsome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Axsome Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Axsome Therapeutics, talking to its executives and customers, or listening to Axsome conference calls.
Axsome Analyst Advice Details

Axsome Stock Analysis Indicators

Axsome Therapeutics stock analysis indicators help investors evaluate how Axsome Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Axsome Therapeutics shares will generate the highest return on investment. By understating and applying Axsome Therapeutics stock analysis, traders can identify Axsome Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow86.5 M
Common Stock Shares Outstanding40.7 M
Total Stockholder Equity109.6 M
Property Plant And Equipment Net420.3 K
Retained Earnings-596.3 M
Cash200.8 M
Accounts Payable38.6 M
Net Debt94.7 M
50 Day M A65.8102
Total Current Liabilities96.6 M
Other Operating Expenses235 M
Non Current Assets Total85.8 M
Non Currrent Assets Other15.4 M
Stock Based Compensation37.7 M
Check out Trending Equities. To learn how to invest in Axsome Stock please use our How to Invest in Axsome Therapeutics guide. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Axsome Therapeutics price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Bond Directory
Find actively traded corporate debentures issued by US companies
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEO Directory
Screen CEOs from public companies around the world
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Return On Assets
Return On Equity
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Axsome Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.